Author(s):
Tanushree C, Suma R, Brian. Peter. Lopes, Aisha Khanum
Email(s):
tanu177@rediffmail.com
DOI:
10.52711/0974-360X.2026.00078
Address:
Tanushree C*1, Suma R2, Brian. Peter. Lopes3, Aisha Khanum4
1,2,3,4Al-Ameen College of Pharmacy, Bangalore - 560027, Karnataka, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 2,
Year - 2026
ABSTRACT:
OAB syndrome, or overactive bladder, is a long-term medical issue that significantly affects a large portion of the population's quality of life in the geriatric populace. Mirabegron is a BCS Class III drug with poor bioavailability and lack of solubility to show quick response. Mirabegron exerts its effect by relaxing the detrusor muscle through selective activation of ß3-adrenergic receptors, resulting in increased bladder capacity and decreased urgency. The work aimed to develop an oral disintegrating tablet containing mirabegron thereby improving the solubility and overcoming poor bioavailability. An oral disintegrating tablet of mirabegron was prepared by lyophilization technique. Menthol is used as a pore-forming agent. Sucrose is applied as an improvement in flavoring agent. The orally disintegrating tablet Weight variation, wetting time, friability, disintegration time, and content homogeneity were assessed along with ex vivo permeation and in vitro studies. The optimized formulation F7 showed uniform drug content, disintegrated, and wetted in less than one minute. The studies on friability showed that the tablets had good mechanical strength. Ex vivo permeation studies proved good solubility and better permeation because of the porous character of the tablets developed by the lyophilization method. In light of the results, it may be said that the developed oral disintegrated tablet equipped with uniform-size and porous nature enhanced dissolution which led to enhanced oral bioavailability of mirabegron.
Cite this article:
Tanushree C, Suma R, Brian. Peter. Lopes, Aisha Khanum. Innovative Drug Development for Geriatric Overactive Bladder: Formulation and Assessment of Orally Disintegrating Tablets. Research Journal of Pharmacy and Technology. 2026;19(2):535-1. doi: 10.52711/0974-360X.2026.00078
Cite(Electronic):
Tanushree C, Suma R, Brian. Peter. Lopes, Aisha Khanum. Innovative Drug Development for Geriatric Overactive Bladder: Formulation and Assessment of Orally Disintegrating Tablets. Research Journal of Pharmacy and Technology. 2026;19(2):535-1. doi: 10.52711/0974-360X.2026.00078 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-2-7
9. REFERENCES:
1. Khanum A, Pandit V, Bhaskaran S, Banu V. Preparation and Evaluation of Tolterodine Tartarate Transdermal Films for the Treatment of Overactive Bladder. Res J Pharm Tech. 2008; 14: 516-21.
2. Malode SS, Wagh MP. Formulation and Evaluation of Orodispersible Tablets Containing Taste Masked Mirabegron Resinate. Res J Pharm Tech. 2021; 14: 94736-2.
3. Nandhakumar S, Sugreevudu G, Harikrishnan N. Formulation design and Evaluation of Extended-Release Tablets of Oxybutynin for Effective Management of Overactive Bladder Syndrome. Res J Pharm Tech. 2021; 14: 126558-4.
4. Jose S, Anukrishna VP, Ajayan AK, Gopi M, Rajendran R, Vijayan M. A Comparative Study on the effectiveness and Tolerability of Mirabegron and Antimuscarinics in the treatment of Overactive bladder. Res J Pharm Tech. 2023; 16: 52369-4.
5. Dudhrejiya AV, Pithadiya SB, Vyas AJ, Patel NK, Patel AI, Gavit HB, Gol DA. RP-HPLC Method Development and Validation for Simultaneous Estimation of Mirabegron and Silodosin in Synthetic Mixture. Res J Pharm Tech. 2024; 17: 94247-2.
6. Bhusari VK, Lonkar AB, Dey RU, Ghante MR. Alcohol-Induced Dose Dumping: A Comparative Study of Marketed Formulation of Mirabegron Tablets by UV and HPLC. Res J Pharm Tech. 2025; 18: 31028-3.
7. Malode SS, Wagh MP. Formulation and Evaluation of Orodispersible Tablets Containing Taste Masked Mirabegron Resinate. Res J Pharm Tech. 2021; 14: 94736-42.
8. Meng E, Lin WY, Lee WC, Chuang YC. Pathophysiology of overactive bladder. LUTS. 2012; 4: 48-55.
9. Latini JM, Giannantoni A. Pharmacotherapy of overactive bladder: epidemiology and pathophysiology of overactive bladder. Expert Opin Pharmacother. 2011; 11: 2710-27.
10. Parijat P, Mandeep D. Orally disintegrating tablets: A review. 2016; 51:50-62.
11. Emine E, et al. Orally Disintegrating Tablets: A short review. 2018; 76-81.
12. Gugulothu D, Desai P, Pandharipande P, Patravale V. Freeze drying exploring potential in development of orodispersible tablets of sumatriptan succinate. Drug Dev Ind Pharm. 2015; 44: 1398-405.
13. Vanbillemont B, De Beer T. Application of polyvinyl acetate in an innovative formulation strategy for lyophilized orally disintegrating tablets. Int J Pharm. 2020; 588: 119717.
14. Lai F, Pini E, Corrias F, Perricci J, Manconi M, Fadda AM, Sinico C. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying. Int J Pharm. 2014 Jun; 546:227-33.
15. Suray H, Shaimaa NA. Formulation and Evaluation of Optimized Zaltoprofen Lyophilized Tablets by Zydis Technique. Iraqi J Pharm Sci. 2017; 26: 140-9.
16. Surawase RK, Baheti KG. Box Behnken Design for Optimization of Mirabegron Solid Dispersion by Fluidized Bed Processing. Res J Pharm Tech. 2022; 15: 41472-6.
17. Mandpe P, Prabhakar B, Shende P. 2^3 Full factorial design for optimization of stable amorphous host–guest-based mirabegron complex for extended-release action. J Inclusion Phen Macrocyclic Chem. 2020 Feb; 96: 111-23.
18. Gulsun T, Cayli YA, Izat N, Cetin M, Oner L, Sahin S. Development and evaluation of terbutaline sulfate orally disintegrating tablets by direct compression and freeze drying methods. J Drug Deliv Sci Technol. 2018 Aug; 14: 6251-8.
19. Ouslander JG. Management of overactive bladder. N Engl J Med. 2004 Feb; 350: 8786-99.
20. Elshafeey AH, El-Dahmy RM. Formulation and development of oral fast-dissolving films loaded with nanosuspension to augment paroxetine bioavailability; In vitro characterization, ex vivo permeation, and pharmacokinetic evaluation in healthy human volunteers. Pharmaceutics. 2021 Nov; 13: 11869.
21. Kulkarni NS, Gite PD, Munde MK, Dhole SN, Khiste RH. A Comprehensive Review on Application of Microwave Irradiation for preparation of Inclusion Complexes with Cyclodextrins. Res J Pharm Tech. 2021; 14: 21131-6.
22. Paul Y, Tyagi S, Singh B. Formulation and evaluation of oral dispersible tablets of zidovudine with different superdisintegrants. Int J Curr Pharm Rev Res. 2011; 2: 280-5.
23. Jagdale SC, Chabukswar AR, Kuchekar BS, Padalkar AN, Kale AU. Comparative Evaluation of Superdisintegrants with Formulation Development of Orodispersible Tablets of Mosapride Citrate Dihydrate. Res J Pharm Tech. 2009; 2: 91-6.
24. Mohire NC, Yadav AV, Gaikwad VK. Novel Approaches in Development of Metronidazole Orodispersible Tablets. Res J Pharm Tech. 2009; 2: 283-6.